Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders
NCT07365059Phase 1Not yet recruiting
- Sponsor
- Qideng Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of GPRC5D CAR-T cell in plasma cell dyscrasia (PCD), sponsored by Qideng Pharmaceutical. Primary endpoints: Adverse Events at 2 years and Overall Response Rate at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
GPRC5D CAR-T cell
03
Conditions
plasma cell dyscrasia (PCD)
Beyond the preview
Go deeper on NCT07365059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365059.